Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2

Trial Profile

Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esketamine (Primary)
  • Indications Tinnitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TACTT2
  • Sponsors Auris Medical
  • Most Recent Events

    • 13 Mar 2018 According to an Auris Medical media release, the Company is investigating the outcomes and will provide an update in due course.
    • 26 Feb 2018 According to Auris Medical media release, Elias Michaelides, MD (Yale School of Medicine) participated as the principal investigator for this trial.
    • 01 Sep 2017 Results assessing safety and tolerability of repeated intratympanic administration of the gel-formulated NMDA receptor antagonist AM-101 in acute patients with inner ear tinnitus, were published in the Otolaryngology - Head and Neck Surgery.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top